


EXHIBITOR HALL MAP



2026 EXHIBITORS


EXHIBITOR	Booth Number
Agendia	104
Ambry Genetics	T12
AstraZeneca	202
Becton Dickinson	12
Breast Cancer Index	T19
BriaCell	T22
CancerNetwork	T13
Cardinal Health	T6
Caris Life Sciences	10
Daiichi Sankyo	303
Elucent Medical	T2
Exact Sciences	11
Foundation Medicine	T24
Genentech	301
Gilead	203
Guardant Health	T8
Hologic	T1
Impedimed	T14
Jazz Pharmaceuticals	T10
Kubtec Medical Imaging	T5
LabCorp Oncology	T17
Lilly	201

EXHIBITOR	Booth Number
Lilly Medical	103
LumiCell	T11
Memorial Sloan Kettering	T26
Menarini Stemline	304
Menarini Stemline Medical	102
Merck & Co.	205
Miami Baptist	T21, T27
Natera	T7
Novartis	204
Novartis Medical	105
OncLive	T23
OncLive Podcast	9006
Paxman Scalp Cooling	T3
Puppy Booth	9
PER®	100
Personalis	T16
Pfizer Oncology	302
PreludeDX	T4
Stryker	T25
Vertex Pharmaceuticals	13

*Information accurate at time of printing.

Thursday, March 5, 2026

Radiation, Surgery, Nursing, Other



Poster #	Abstract title	Digital Download
001	Real-World Outcomes of Radiation Omission After Breast-Conserving Surgery in Older Women with Stage I ER-Positive Breast Cancer: A SEER Analysis (2000–2022)	
002	Ten-year Outcomes of Moderately Hypofractionated Breast/Chest Wall Radiotherapy with Simultaneous Integrated Boost (SIB)	
003	Rapid Uptake of 5-Fraction Breast Radiotherapy in the U.S. (NCDB 2020–2023) With Persistent Access Disparities	
004	National Adoption of Ultra-Hypofractionated (5-Fraction) External Beam Radiation Therapy in the United States, 2020–2023: An NCDB Analysis	
005	Perioperative Radiotherapy for Malignant Phyllodes Tumors: Evidence Summary and Practical Considerations for Chest-Wall Interstitial HDR Brachytherapy	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/005_MBCC26_Kornienko_phyllodes_Thu.pdf
006	Breast Imaging Access and Geographic Inequality in Miami-Dade County: Implications for Diagnostic Delay and Stage at Presentation	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/006_MBCC26_Warren_BreastImagingAccess_Thu.pdf
007	Harnessing Machine Learning to Measure Access to Health Care	

Poster #	Abstract title	Digital Download
008	Mammography Uptake Among U.S. Women Aged 40–49: An Andersen Behavioral Model Analysis Using 2019-2023 NHIS Data	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/008_MBCC26_Akter_mammographyuptake_Thu.pdf
009	Radiologists' and Ultrasound Artificial Intelligence Decision-Support Assessment of Benign and Malignant Cystic Breast Lesions	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/009_MBCC26_Rooney_Cys_Abstract.pdf
010	Abnormality-Focused Two-Phase Deep Learning for Mammographic Lesion Segmentation: Strategies and Limitations	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/010_MBCC26_Alkadri_2phaselearning_Thu.pdf
011	Trends in Breast cancer among Indian women: analysis of global burden of Diseases from 1990-2023	
012	Validation of a Multimodal Artificial Intelligence Prognostic Model in Early-Stage HR+/HER2– Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/012_MBCC26_Pawar_MultimodalAI_Thu.pdf
013	Assessing the Quality and Reliability of Online Health Information for Breast Pathology: Search Engines versus Large Language Models	
014	Advancing Breast Cancer Diagnosis in Rural Kenya: Bridging Histopathological Gaps Towards Global Breast Cancer Initiative (GBCI) Goals	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/014_MBCC26_Ngonga_Kenya_Thu.pdf
015	Technique of Surgeon-Performed Intraoperative Regional Pectoral Nerve Block for Patients Undergoing Mastectomy	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/015_MBCC26_Weinand_PectoralNerveBlock_Thu.pdf
016	Local Recurrence and Contralateral Breast Cancer Risks in Patients With Family History Are Comparable to Population-Based Data: A Single-Center Experience of 278 Cases	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/016_MBCC26_Celik_Localrecurrence_Thu.pdf
017	Modified oncoplastic technique for multifocal breast cancer: a single-center experience	
018	Advanced Oncoplastic Breast Surgery Using Multiple Pedicles Following Breast-Conserving Surgery: Oncologic and Surgical Outcomes	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/018_MBCC26_Chahine_pedicles_Thu.pdf
019	Targeted Axillary Dissection- does the biopsy-proven node need to be localized? A retrospective review of patients with node-positive breast cancer treated with neoadjuvant systemic therapy	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/019_MBCC26_Smith_targetedaxillarydissection_Thu.pdf

Poster #	Abstract title	Digital Download
020	On The Upswing: A Retrospective Cohort Study Evaluating Neoadjuvant Chemotherapy Response in Metaplastic Breast Cancer Patients	
021	Body Mass Index and its Association With Pathological Response in Breast Cancer Patients in Venezuela	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/021_MBCC26_Ojeda_BMI_Thu.pdf
022	Implications of SOUND Trial on Adjuvant Radiation Therapy in Early Stage Breast Cancer Patients	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/022_MBCC26_Rozenberg_SOUND_Thu.pdf
023	Implementation of Choosing Wisely Recommendations for Omission of Sentinel Lymph Node Biopsy in Elderly Patients with Early-Stage Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/023_MBCC26_Brod_CW-GuideOmissSLNB_Thu.pdf
024	Estimated rate of malignancy in breast lesions after discordant pathology and imaging	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/024_MBCC26_Coomes_ImagePathDiscordance_Thu.pdf
025	Evaluating the Impact of In-Office Genetic Testing on Uptake and Equity in Breast Cancer Patients: A Retrospective Cohort Study	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/025_MBCC26_Alilio_in-officegeneTest_Thu.pdf
026	A Nomogram for Predicting High Axillary Disease Burden in Patients with Localized HR+, HER-2-negative Breast Cancer Following Neoadjuvant Chemotherapy	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/026_MBCC26_Kalakuntla_nomogram_Thu.pdf
027	Transfusion and Anemia Management Strategies in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy: A Literature Review	
028	A cost-utility analysis comparing indocyanine green to methylene blue dye in axillary lymphatic mapping and sentinel lymph node biopsy for breast cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/028_MBCC26_Lee_IC-GvsMBcost-utility_Thu.pdf
029	A demonstration of opportunity cost in surgical delays when using needle localization versus MOLLI localization in breast surgery	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/029_MBCC26_Lee_MOL-Lloppportunitycost_Thu.pdf
030	Accuracy and operational efficiency of the MOLLI marker compared to needle localization in breast surgery	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/030_MBCC26_Lee_MOL-Lloutcomes_Thu.pdf
031	E-strain Elastography as an Adjunct of Breast Ultrasound: Impact on Biopsy Decision-Making	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/031_MBCC26_Ahmed_E-strain_Thu.pdf

Poster #	Abstract title	Digital Download
032	Primary Breast Neuroendocrine Carcinoma with Synchronous Pancreatic and Liver Metastases: Literature Review of Management Considerations for an Exceptionally Rare Presentation	
033	Pyoderma Gangrenosum Mimicking Post-Mastectomy Flap Failure: Management Lessons from a Contemporary Case and Literature Review	
034	Withdrawn	
035	MagUS (Magnetically-guided UltraSound) Core Needle Biopsy of the Sentinel Lymph Nodes. Avoidance of axillary surgery in patients unsure of de-escalation	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/035_MBCC26_Menen_MagUS_Thu.pdf
036	Correlation between disseminated cancer cells and DCISionRT predictor score in patients with ductal carcinoma in situ	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/036_MBCC26_Ackerman_DCISionRT_Thu.pdf
037	Evaluating Barriers to Home Recovery After Mastectomy at a Single Hospital System	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/037_MBCC26_MShpi-gel_homerecovery_Thu.pdf
038	[P]ostoperative [A]nalgesia and [I]nvestigating [N]arcotics in Breast Cancer Patients; Protocol BHWGI 24-01: PAIN	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/038_MBCC26_Soran_PAIN_Thu.pdf
039	Predictors of Delay in Time from Diagnostic Breast Imaging to Needle Core Biopsy	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/039_MBCC26_Syed_Delayspredictors_Thu.pdf
040	An AI Digital Twin Compares Favorably to Radiologists for Landmark Identification and Measurement in Early-Stage Breast Cancer: A Retrospective, Multi-Institution Clinical Study	
041	Unexpected while expecting: rare case of pregnancy associated xanthogranulomatous mastitis masquerading as malignancy	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/041_MBCC26_Syed_XGM_Thu.pdf
042	Intraoperative Frozen Analysis of Sentinel Lymph Nodes After Neoadjuvant Chemotherapy Does Not Improve Surgical Outcomes and Increases Unnecessary ALND in Clinically Node-Negative Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/042_MBCC26_Emiroglu_intraoperativeFrozen_Thu.pdf
043	The Next Generation MarginProbe® Device: Incremental Performance Gains in an Area of Persistent Unmet Need	

Poster #	Abstract title	Digital Download
044	Long-Term Oncological Outcomes After Oncoplastic Therapeutic Mammoplasty With Contralateral Symmetrisation for Early Breast Cancer: A Thirteen-Year Single-Centre Cohort Study	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/044_MBCC26_Pitsinis_longTerm_Thu.pdf
045	Use of Preoperative Ultra-hypofractionated Radiotherapy in Patients with Locally Advanced Breast Cancer: Clinical and Pathological Outcomes	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/045_MBCC26_Gabler_preoperativeultrafrackRx_Thu.pdf
046	Improving Breast Cancer Related Lymphedema and Upper Extremity Dysfunction: Why Multidisciplinary Care Matters	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/046_MBCC26_Katz_Lymphedema_Thu.pdf
047	Effect of Postmastectomy Radiation Therapy on Outcomes for Implant-Based Reconstruction	
048	Validation of a Multi-omic Biosignature to Predict Locoregional Recurrence Risk and the Benefit of Adjuvant Radiation Therapy in Women with Early-Stage Invasive Breast Cancer Treated with Breast-Conserving Surgery and Endocrine Therapy.	
049	The PREDICT II Registry: A Prospective Study to Evaluate the Clinical Utility of a 7-Gene Predictive Biosignature on Treatment Decisions in Patients with Ductal Carcinoma In Situ	
050	Randomized Clinical Trial of Standard Verbal Counseling with or without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients with Stage 0-IIIa Breast Cancer Receiving Radiation Therapy (COPE Study)	
051	Metastasis-Directed Therapy and Local-Regional Therapy for Patients with Metastatic Breast Cancer: Who, What, Where, and When?	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/051_MBCC26_Patel_OMBC_MDT_Thu.pdf
052	“There’s no place like home”: Best Practices Bringing Cutting Edge Breast Cancer Treatments Closer to Home	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/052_MBCC26_YEN_ClinicalTrialEnrollment_Thu.pdf
053	U.S. patient perspectives on capivasertib plus fulvestrant: dosing, tolerability, and blood glucose monitoring from qualitative interviews	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/053_MBCC26_Park_CapiPatient_Thu.pdf
054	Pleomorphic invasive lobular carcinoma: Multimodality imaging findings in cases from the University of Rochester Medical Center.	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/054_MBCC26_Kaddu_Pleomorphic_Thu.pdf

Poster #	Abstract title	Digital Download
055	Intramammary Spindle-Cell Lesions: Imaging–Pathology Correlation	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/055_MBCC26_Gianni_Spindle-CellLesions_Thu.pdf
056	Prospective Study of quantitative near-infrared spectroscopy for noninvasive assessment of suspicious breast lesions	
057	Altered biomechanics drives outcome in breast cancer: a new avenue for oncology biomarkers	
058	An Evidence-Based Self-Management Planner for Patients With Metastatic Triple-Negative Breast Cancer: A Multi-Channel Dissemination Initiative	
059	Structural Racism and Insurance Disadvantage as Mediators of Racial Disparities in Breast Cancer Stage at Diagnosis	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/059_MBCC26_Itinoche_racialdisparities_Thu.pdf
060	Structural Racism and Insurance Disadvantage as Mediators of Racial Disparities in Triple-Negative Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/060_MBCC26_Patel_TNBC_Thu.pdf
061	Economic Burden of Neutropenia Among Patients Treated for HR+/HER2- and Triple-negative Metastatic Breast Cancer in the United States: A Retrospective Claims Analysis	
062	Integrating dose modifications for effective management of HR+, HER2– early breast cancer with abemaciclib	
063	Patient- and Provider- Related Diagnostic Delay in Pregnancy-Associated Breast Cancer: A Descriptive Systematic Review	tp://mjh-site-content.s3.amazonaws.com/creative/MBC_26/063_MBCC26_Lindsey_diagnosticdelay_Fri.pdf
064	A Phase I/II Study of Pembrolizumab and Anti-CD3 x Anti-HER2 Armed Activated T-Cells in Metastatic Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/064_MBCC26_Begun_HER2BATsPBZ_Fri.pdf
065	The Impact of Aromatase Inhibitor Use on Cardiorespiratory Fitness in Post-Menopausal Breast Cancer Patients	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/065_MBCC_Begun_ExerciseAI_Fri.pdf
066	Feasibility of the THRIVE Wellness Program for Young Breast Cancer Survivors: A Multicenter Pilot Trial	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/066_MBCC26_devjani_feasibility_Fri.pdf

Poster #	Abstract title	Digital Download
067	Spirituality and Medical Trust Among Breast Cancer Outpatients in an Urban Safety-Net Setting	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/067_MBCC26_devjani_spiritualitytrust_Fri.pdf
068	Breast Cancer Stem Cells and Genomic Drivers of Therapeutic Resistance	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/068_MBCC26_Paudel_Stemcells_Fri.pdf
069	Assessing the Impact and Efficacy of Anthracyclines and Trastuzumab Alternatives on Potential Cardiotoxicity in Breast Cancer Patients	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/069_MBCC26_Patel_cardiotoxicity_Fri.pdf
070	Real-World Outcomes and Toxicity of Trastuzumab Deruxtecan in Older Adults With Breast Cancer: A Mayo Clinic Multi-Site Analysis	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/070_MBCC26_Mahadevia_RWOTDXd_Fri.pdf
071	Timing of Neoadjuvant Immunotherapy and Pathological Response in Early-Stage Triple Negative Breast Cancer: A Literature Review and Case Series	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/071_MBCC26_Zou_timingneoadjTNBC_Fri.pdf
072	Clonal Hematopoiesis and Anthracycline Cardiotoxicity in Breast Cancer: A Missed Opportunity in Cardio-Oncology Risk Stratification?	
073	The ADC Era in Breast Cancer: Contemporary Sequencing Strategies and Evidence-Based Toxicity Management	
074	Real-World Study Characterizing Patient Characteristics, Treatments, and Unmet Need in IO-Ineligible Patients With Metastatic Triple-Negative Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/074_MBCC26_Nguyen_DSI03051_P360_mTNBC_Fri.pdf
075	Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Real-World Treatment Patterns and Outcomes From Community Oncology Settings	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/075_MBCC26_Nguyen_t-dxd_her2-low_Fri.pdf
076	Real-World Safety of Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer: Insights From US Community Oncology Practices	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/076_MBCC26_Walker_t-dxd_her2-low_insights_Fri.pdf
077	Updated Efficacy of Mutant-Selective PI3K α Inhibitor Zovegalisib (RLY-2608) in Combination with Fulvestrant in Patients with PIK3CA-Mutant HR+HER2- Advanced Breast Cancer: ReDiscover Trial	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/077_MBCC26_Sammons_zovegalisib_Fri.pdf



Poster #	Abstract title	Digital Download
078	Liquid Biopsy Insights: Genomic Drivers of Endocrine Resistance in Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/078_MBCC26_Ko_Liquid-biopsy_Fri.pdf
079	An Exploration of the Influence of Adverse Childhood Experiences (ACEs) upon Symptom Burden & Tolerance of Anti-Estrogen Therapy (AET) in Breast Cancer Patients	

Friday, March 6, 2026

Medical Oncology

Attendee, Exhibitor, Faculty, and Press Check-in

068	078	088	098	108	118	128	138	
067	077	087	097	107	117	127	137	
069	079	089	099	109	119	129	139	
066	076	086	096	106	116	126	136	146
070	080	090	100	110	120	130	140	
065	075	085	095	105	115	125	135	145
071	081	091	101	111	121	131	141	
064	074	084	094	104	114	124	134	144
072	082	092	102	112	122	132	142	
063	073	083	093	103	113	123	133	143

Poster #	Abstract title	Digital Download
080	Datopotamab Deruxtecan (Dato-DXd) + Durvalumab (D) as First-Line (1L) Treatment (tx) for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer (a/ mTNBC): Final Results From the Phase 1b/2 BEGONIA Study	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/080_MBCC26_Ma_BE-GONIAArms7and8_Fri.pdf
081	A First-in-Human Study of a Selective ERBB2 Inhibitor, CGT4255, in Patients who have Advanced Solid Tumors with ERBB2 Genetic Alterations or HER2 Overexpression	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/081_MBCC26_Westphalen_ERBB2CGT4255_Fri.pdf
082	Facilitators and Barriers to Clinical Trial Participation in Metastatic Breast Cancer: Patient and Physician Perspectives to Advance Representation	

Poster #	Abstract title	Digital Download
083	Breast Cancer Prevalence Among Older Immigrant Women in the United States: A Cross-Sectional Study	
084	Exceptional responders in de novo metastatic breast cancer (dnMBC) drug cessation in patients with HER2 Positive Metastatic Breast Cancer; multicenter retrospective study	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/084_MBCC26_Soran_Exceptional_Fri.pdf
085	rwpCR and rWEFS in Early-Stage Triple-Negative Breast Cancer Patients from Community Oncology are Concordant with Trial Endpoint Estimates	
086	Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-line (2L) Treatment of Patients with HR+/HER2-/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Updated Results from VIKTORIA-1	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/086_MBCC26_Pistilli_updatedVIKTORIA_Fri.pdf
087	Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-line (2L) Treatment of Patients with HR+/HER2-/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results from VIKTORIA-1	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/087_MBCC26_Hurvitz_VIKTORIA_Fri.pdf
088	Imlunestrant with or without abemaciclib in advanced breast cancer (ABC): a subgroup analysis in CDK4/6 inhibitor (CDK4/6i)-pretreated patients from EMBER-3	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/088_MBCC26_Pring-Pring_Pstr88_Fri.pdf
089	Imlunestrant with or without abemaciclib as first- and second-line therapy in advanced breast cancer (ABC): a subgroup analysis from the EMBER-3 trial	
090	Real-world ESR1 Mutation and Testing Rates in Patients with ER+, HER2- Metastatic Breast Cancer	
091	Real-world survival outcomes by risk features in patients with HR+, HER2- early breast cancer in the United States	
092	Abemaciclib after Abemaciclib: A Real-World Comparative Analysis Challenging the Paradigm of Sequential CDK4/6 Inhibitors in Metastatic Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/092_MBCC26_Wander_AbemaPostAbema_Fri.pdf
093	monarchE: Primary overall survival results of adjuvant abemaciclib + endocrine therapy for HR+, HER2-, high-risk early breast cancer	
094	Treatment Persistence and Dose Modifications in US Patients with HR+, HER2-, Node-Positive, Early Breast Cancer Treated with Adjuvant Abemaciclib	



Poster #	Abstract title	Digital Download
095	monarchE: Subgroup Analysis of Adjuvant Abemaciclib + Endocrine Therapy for HR+, HER2-, High-risk Early Breast Cancer by Nodal Status	
096	Efficacy and safety of abemaciclib in younger patients with early breast cancer in the monarchE trial	
097	monarchE: Evaluation of prognostic and predictive value of Ki-67 index pre and post neoadjuvant chemotherapy and changes following NAC	
098	A Phase 1/2 Trial of LY4064809, A Pan-mutant-selective PI3Kα Inhibitor in HR+, HER2- Advanced Breast Cancer, Updated Results from PIKALO-1	
099	Imlunestrant with or without abemaciclib in advanced breast cancer: Updated efficacy results from the phase 3 EMBER-3 trial	
100	Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer (ABC): An indirect treatment comparison (ITC) of three phase 3 trials	
101	Patient-reported outcomes (PROs) in patients with ER+, HER2- advanced breast cancer (ABC) treated with imlunestrant, investigator's choice standard endocrine therapy, or imlunestrant+abemaciclib: Results from the phase III EMBER-3 trial	
102	Imlunestrant (imlu) with or without abemaciclib (abema) in advanced breast cancer (ABC): Safety analyses from the phase III EMBER-3 trial	
103	Randomized phase 3 clinical trial evaluating atirmociclib plus letrozole versus a CDK4/6 inhibitor plus letrozole as first-line treatment for patients with HR+/HER2- advanced/metastatic breast cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/103_MBCC26_Bidard_CDK4iTiP_Fri.pdf
104	KATSIS-1: Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 (prifetrastat) plus fulvestrant in HR+HER2- advanced/metastatic breast cancer after progression on CDK4/6 inhibitor-based therapy	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/104_MBCC26_Kalinsky_KAT6iPh3TiP_Fri.pdf
105	Real-world overall survival with palbociclib plus an aromatase inhibitor (AI) in overweight/obese patients with HR+/HER2- metastatic breast cancer (MBC)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/105_MBCC26_Brufsky_FlatironObesityPoster_Fri.pdf

Poster #	Abstract title	Digital Download
106	Treatment Durations, Subsequent Treatments, and Switching of First-Line Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with HR+/HER2- Metastatic Breast Cancer in US Routine Clinical Practice	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/106_MBCC26_Brufsky_PVERIFYTrtPatt_Fri.pdf
107	Updated Results and an Exploratory Analysis of ESR1 Mutations (ESR1m) Circulating Tumor DNA (ctDNA) Dynamics From SERENA-6, a Phase III Trial of Camizestrant + CDK4/6 Inhibitor (CDK4/6i) for Emergent ESR1m During First-Line (1L) Endocrine-Based Therapy and Ahead of Disease Progression in Patients With HR+/HER2- Advanced Breast Cancer (ABC)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/107_MBCC26_Brufsky_SERENA-6DCO2PFS_Fri.pdf
108	Long-term safety and efficacy of first-line next generation CDK4-selective inhibitor atimociclib + letrozole for the treatment of patients with HR+/HER2- metastatic breast cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/108_MBCC26_Yap_CD-K4i+LET_Fri.pdf
109	Extended Adjuvant Neratinib in HER2+/HR+ Early Breast Cancer in Clinical Routine: Final Results from the Multi-national, Prospective, Observational Study ELEANOR	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/109_MBCC26_Luftner_ELEANOR_Fri.pdf
110	Randomized Phase II Trial Evaluating Three Anti-diarrheal Prophylaxis Strategies in Patients (pts) with HER2+/HR+ Early Breast Cancer (EBC) Treated with Extended Adjuvant Neratinib (Dianer Geicam/2018-06)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/110_MBCC26_GilGil_DIANER_Fri.pdf
111	The Aurora Kinase A Inhibitor Alisertib Alone or in Combination with Endocrine Therapy for Patients with Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Metastatic Breast Cancer (MBC)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/111_MBCC26_Haddad_Alisertib_Fri.pdf
112	First-Line (1L) Datopotamab Deruxtecan (Dato-DXd) vs Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (mTNBC) for Whom Immunotherapy was not an Option: Primary Results From the Randomized, Phase 3 TROPION-Breast02 Trial	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/112_MBCC26_Dent_TB02primaryanalysis_Fri.pdf
113	HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/113_MBCC26_Meric-Bernstam_HERTHENA-PanTumor01_TiP_Fri.pdf
114	Comparing an AI-based prognostic test with a 21-gene assay for recurrence prediction in premenopausal node-positive HR+ HER2- breast cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/114_MBCC26_Elayoubi_premenopausal_Fri.pdf

Poster #	Abstract title	Digital Download
115	Evaluating an AI-based prognostic test to guide adjuvant CDK4/6 inhibitor selection in early HR+/HER2- breast cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/115_MBCC26_McAndrew_cdk46eligibility_Fri.pdf
116	Impact of neoadjuvant chemotherapy (NACT) response on clinical outcomes with ribociclib (RIB) in HR+/HER2- EBC: a subgroup analysis from the phase 3 NATALEE trial	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/116_MBCC26_McAndrew_NATALEE-NeoadjCT_Fri.pdf
117	Risk of Recurrence (ROR) Among Patients With HR+/HER2- Early Breast Cancer (EBC) Involving 1-3 Axillary Lymph Nodes (N1): A Real-World Evaluation	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/117_MBCC26_Razavi_RIBRANT_N1_Fri.pdf
118	Pooled analysis of patients treated with 1st-line (1L) ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) studies: long-term progression-free survival (PFS)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/118_MBCC26_Andre_MLLongTermResp_Fri.pdf
119	Progression-free survival (PFS) and overall survival (OS) results from the phase 3 MONALEESA-3 trial of postmenopausal patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL): a subgroup analysis of patients with invasive lobular carcinoma (ILC)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/119_MBCC26_DeLaurentiis_ML3obularPFSOS_Fri.pdf
120	REPOWER: a real-world noninterventional study of outcomes and experiences in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) treated with an adjuvant cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) plus endocrine therapy (ET)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/120_MBCC26_Lustberg_RWE_REPOWER_TiP_Fri.pdf
121	Five-year analysis of distant disease-free survival (DDFS) across key subgroups from the phase 3 NATALEE trial of ribociclib (RIB) plus a nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early breast cancer (EBC)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/121_MBCC26_Hurvitz_NATALEE5y-LMDDFS_Fri.pdf
122	Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients with HR+/HER2- early breast cancer (EBC): NATALEE 5-year outcomes	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/122_MBCC26_Crown_NAT5y_Poster_Fri.pdf
123	Real-World Patient and Caregiver Experiences With Breast Cancer (BC) Risk of Recurrence (ROR) in the US: Results of an Online Survey and Social Media Analysis	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/123_MBCC26_Rugo_SMLCarenity_Fri.pdf

Poster #	Abstract title	Digital Download
124	Real-world progression-free survival 2 and tumor response of CDK4/6is + aromatase inhibitor in patients with HR+/HER2– metastatic breast cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/124_MBCC26_Rugo_RW-PFSCDK_Fri.pdf
125	ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/125_MBCC26_Rugo_Re-Discover-2_Fri.pdf
126	TroFuse-011: a Phase 3, Randomized, Open-Label Study of Sacituzumab Tirumotecan With or Without Pembrolizumab vs Treatment of Physician's Choice for Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer With PD-L1 Combined Positive Score <10	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/126_MBCC26_Rugo_TroFuse-011TiP_Fri.pdf
127	TroFuse-012: a Phase 3, Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment Of Physician's Choice in Participants With Triple-Negative Breast Cancer who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery	
128	TroFuse-032: a Phase 3, Randomized Study of Pembrolizumab Plus Sacituzumab Tirumotecan or Chemotherapy Followed by Pembrolizumab plus Chemotherapy for Early-Stage Triple-Negative Breast Cancer or Hormone Receptor-low–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/128_MBCC26_Schmid_TroFuse-032TiP_Fri.pdf
129	The Role of Vitamin CDK 4-6 Inhibitor Therapy for Breast Cancer	
130	Sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in previously untreated PD-L1–positive advanced triple-negative breast cancer (TNBC): primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/130_MBCC26_Tolaney_BC_TrodelvyA-04_Fri.pdf
131	Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/131_MBCC26_Cortes_BC_TrodelvyA-03_Fri.pdf

Poster #	Abstract title	Digital Download
132	Characteristics and Treatments of Patients Receiving Two or More Lines of Treatment for Metastatic Triple-Negative Breast Cancer in the US Community Health Setting	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/132_MBCC26_Stwalley_RW_Tx_Patt_mTNBC_Fri.pdf
133	Racial Disparities in Biomarker Testing, Treatment Utilization, and Outcomes in Patients with Metastatic Triple-Negative Breast Cancer (mTNBC) in U.S. Community Practices	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/133_MBCC26_Stwalley_TNBCRace_Fri.pdf
134	ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from ER+/HER2- breast cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/134_MBCC26_Ibrahiml_ELECTRA_Fri.pdf
135	Elacestrant in combination with everolimus or abemaciclib in patients with ER+/HER2- locally advanced or metastatic breast cancer (mBC): phase 2 results from ELEVATE, an open-label, umbrella study	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/135_MBCC26_Rugo_ELEVATE_Fri.pdf
136	ELEGANT: Elacestrant Versus Standard Endocrine Therapy (ET) in Women and Men With Node-positive, Estrogen Receptor-positive (ER+), HER2-negative (HER2-), Early Breast Cancer (eBC) With High Risk of Recurrence in a Global, Multicenter, Randomized, Open-label Phase 3 Study	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/136_MBCC26_Bardia_EL-EGANT_Fri.pdf
137	ADELA: A Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus Versus Elacestrant + Placebo in ER+/HER2- Advanced Breast Cancer (aBC) Patients with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/137_MBCC26_Llombart-Cussac_ADELA_Fri.pdf
138	HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib Versus Placebo Added to Trastuzumab and Pertuzumab as Maintenance Therapy for HER2+ Metastatic Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/138_MBCC26_Hamilton_HER2CLIMB05_Fri.pdf
139	Real-world Biomarker Testing in HR+/HER2- Metastatic Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/139_MBCC26_Margolis_biomarkers_Fri.pdf

Poster #	Abstract title	Digital Download
140	Real-World Pharmacological Management of Hyperglycemia in HR-positive/HER2-negative Metastatic Breast Cancer Treated with Capivasertib or Alpelisib	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/140_MBCC26_Iyengar_CapivasertibTolerability_Fri.pdf
141	DESTINY-Breast06 Post Hoc Analysis by Physician's Choice of Chemotherapy: Efficacy and Safety of Trastuzumab Deruxtecan Versus Physician's Choice of Chemotherapy in Hormone Receptor–Positive, HER2-Low or -Ultralow Metastatic Breast Cancer	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/141_MBCC26_Morgan_TPCSubgroups_Fri.pdf
142	Exploratory Biomarker Analysis of Trastuzumab Deruxtecan Versus Physician's Choice of Chemotherapy in HER2-low/ultralow, Hormone Receptor–Positive Metastatic Breast Cancer in DESTINY-Breast06	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/142_MBCC26_Morgan_Biomarkers_Fri.pdf
143	Patient Experience with Intramuscular vs. Oral Endocrine Therapy in Metastatic Breast Cancer	
144	Pregnancy associated breast cancer	
145	Racial Differences in Outcomes and Healthcare Utilization Among Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer Treated With CDK4/6 Inhibitors: A Real-World Analysis	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/145_MBCC26_Amaechi_Trinetex_Fri.pdf
146	Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial	http://mjh-site-content.s3.amazonaws.com/creative/MBC_26/146_MBCC26_Bardia_lidERA_Fri.pdf